Literature DB >> 23602715

Virus-induced CD8+ T cells accelerate the onset of experimental autoimmune encephalomyelitis: implications for how viral infections might trigger multiple sclerosis exacerbations.

Emily K Rainey-Barger1, Pennelope K Blakely, Amanda K Huber, Benjamin M Segal, David N Irani.   

Abstract

Viral infections can exacerbate multiple sclerosis (MS) through poorly defined mechanisms. We developed an experimental system whereby infection with an asymptomatic neurotropic alphavirus caused a transient acceleration of experimental autoimmune encephalomyelitis (EAE) without altering the expansion or differentiation of autoreactive CD4+ T cells. Instead, this effect on the clinical course of EAE depended on CD8+ T cells that neither participate in viral clearance nor induce neuropathology in infected mice without EAE. Our system should be useful to further unravel how certain viral infections trigger MS exacerbations and to understand how CD8+ T cells can exert pathogenic effects within active demyelinating lesions.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23602715      PMCID: PMC3654028          DOI: 10.1016/j.jneuroim.2013.03.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  39 in total

1.  The risk of relapses in multiple sclerosis during systemic infections.

Authors:  Jorge Correale; Marcela Fiol; Wendy Gilmore
Journal:  Neurology       Date:  2006-07-26       Impact factor: 9.910

2.  Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis.

Authors:  Mandy L Ford; Brian D Evavold
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

3.  Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis.

Authors:  M Soilu-Hänninen; M Röyttä; A Salmi; R Salonen
Journal:  J Neuroimmunol       Date:  1997-01       Impact factor: 3.478

4.  Clinical viral infections and multiple sclerosis.

Authors:  W A Sibley; C R Bamford; K Clark
Journal:  Lancet       Date:  1985-06-08       Impact factor: 79.321

5.  Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis.

Authors:  J De Keyser; C Zwanikken; M Boon
Journal:  J Neurol Sci       Date:  1998-07-15       Impact factor: 3.181

6.  Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study.

Authors:  O Andersen; P E Lygner; T Bergström; M Andersson; A Vahlne
Journal:  J Neurol       Date:  1993-07       Impact factor: 4.849

7.  Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis.

Authors:  S Edwards; M Zvartau; H Clarke; W Irving; L D Blumhardt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

8.  Immune responses, and autoimmune outcome, during virus infection of the central nervous system.

Authors:  F Mokhtarian; Y Shi; P F Zhu; D Grob
Journal:  Cell Immunol       Date:  1994-08       Impact factor: 4.868

9.  Predisposition to EAE induction in resistant mice by prior infection with Semliki Forest virus.

Authors:  F Mokhtarian; P Swoveland
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

10.  Synergistic interaction between measles virus infection and myelin basic protein peptide-specific T cells in the induction of experimental allergic encephalomyelitis in Lewis rats.

Authors:  U G Liebert; V ter Meulen
Journal:  J Neuroimmunol       Date:  1993-07       Impact factor: 3.478

View more
  1 in total

1.  Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation.

Authors:  Marjan Vanheusden; Bieke Broux; Suzanne P M Welten; Liesbet M Peeters; Eleni Panagioti; Bart Van Wijmeersch; Veerle Somers; Piet Stinissen; Ramon Arens; Niels Hellings
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.